Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~  * Locally advanced or regional (encompassable within the same radiotherapy portals)~ * Adenosquamous cancers are allowed~* Unresectable disease~* Measurable and/or non-measurable disease as determined by computed tomography (CT) scan or magnetic resonance imaging (MRI), which must be performed within 4 weeks prior to randomization.~* Age\>=18~* ECOG Performance status of 0-1~* Life expectancy \>= 12 weeks~* Adequate bone marrow reserve,liver and renal function within 2 weeks of randomization:~  * Absolute granulocyte count at least 2,000/mm\^3~ * Platelet count at least 100,000/mm\^3~ * Bilirubin less than 3 mg/dL (unless secondary to biliary obstruction or cholangitis)~ * Serum glutamic-oxaloacetic (AST) less than 5 times upper limit of normal (ULN)~ * Albumin greater than 2.5 g/dL~ * Creatinine no greater than 1.5 times ULN~* Fertile patients must use effective contraception~* Willing and able to attend follow-up visits~* Concurrent enrollment on protocol ECOG-E1Y03 allowed~* More than 4 weeks since prior investigational agents~Exclusion Criteria:~* Candidate for surgical excision based on local extent of disease (e.g., T3, N1, M0)~* Stage M1 disease~* Small cell, mucinous cystadenocarcinoma, islet cell or papillary cystic histology~* Pregnant or nursing~* Active infection within within 4 weeks of randomization~* Malignancy within the past 5 years except nonmelanoma skin cancer, carcinoma in situ of the cervix, or organ-confined prostate cancer (Gleason score no greater than 7)~* History of active collagen vascular disease (i.e., systemic lupus erythematosus, rheumatoid arthritis, or scleroderma)~* Signs or symptoms of peptic or duodenal ulcer disease~* Concurrent serious systemic disorders that are incompatible with study participation~* Prior chemotherapy for pancreatic cancer~* Prior radiotherapy~* Concurrent intensity modulated radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine (Type: ACTIVE_COMPARATOR): None
- Gemcitabine + Radiation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).